Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Optimizing radiotherapy for intermediate-risk localized disease

Nature Reviews Urology volume 15, pages 470–471 (2018)Cite this article

Subjects

Dose-intensified radiotherapy is widely used in prostate cancer treatment but its effect on distant metastasis and overall survival is unclear. A large randomized clinical trial to evaluate the role of external-beam-based dose intensification without androgen deprivation therapy in intermediate-risk disease shows that dose escalation can reduce distant metastases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Dose-escalated intensity-modulated radiotherapy (IMRT) reduces distant metastases in men with intermediate-risk localized prostate cancer.

References

  1. Viani, G. A., Stefano, E. J. & Afonso, S. L. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int. J. Radiat. Oncol. Biol. Phys. 74, 1405–1418 (2009).

    Article  PubMed  Google Scholar 

  2. Kuban, D. A. et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 67–74 (2008).

    Article  PubMed  Google Scholar 

  3. Dearnaley, D. P. et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 15, 464–473 (2014).

    Article  PubMed  Google Scholar 

  4. Viani, G. A. et al. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial. Cancer 122, 2004–2011 (2016).

    Article  PubMed  Google Scholar 

  5. Zelefsky, M. J. et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 84, 125–129 (2012).

    Article  PubMed  Google Scholar 

  6. Mottet, N. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 71, 618–629 (2017).

    Article  PubMed  Google Scholar 

  7. Zumsteg, Z. S. et al. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 85, 1012–1017 (2013).

    Article  PubMed  CAS  Google Scholar 

  8. Michalski, J. M. et al. Effect of standard versus dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.0039 (2018).

  9. Hamdy, F. C. et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).

    Article  PubMed  Google Scholar 

  10. Pisansky, T. M. et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J. Clin. Oncol. 33, 332–339 (2015).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany

    Pirus Ghadjar

  2. Department of Radiation Oncology, University of Ulm, Ulm, Germany

    Thomas Wiegel

Authors
  1. Pirus Ghadjar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Wiegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Wiegel.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghadjar, P., Wiegel, T. Optimizing radiotherapy for intermediate-risk localized disease. Nat Rev Urol 15, 470–471 (2018). https://doi.org/10.1038/s41585-018-0024-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-018-0024-y

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing